Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

5
results for

"Stage Liver Disease"

Article category

Keywords

Publication year

"Stage Liver Disease"

Original Article

Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation
Changze Hong, Zuxiong Huang, Yingli He, Rongqi Wang, Jiaying Lin, Yushan Liu, Baicheng Liu, Xiaoqin Lan, Qinjun He, Wenfan Luo, Qintao Lai, Ling Zhou, Tingting Qi, Yali Ji, Miaoxia Liu, Qiaoping Wu, Yichen Yao, Weihao Liang, Xianbo Wang, Guohong Deng, Yanhang Gao, Yan Huang, Feng Liu, Xiaobo Lu, Zhongji Meng, Yuemin Nan, Hai Li, Beiling Li, Rajiv Jalan, Jinjun Chen
Clin Mol Hepatol 2025;31(4):1316-1332.
Published online July 4, 2025
DOI: https://doi.org/10.3350/cmh.2025.0332
Background/Aims
The role of reactivation of human cytomegalovirus (HCMV) in determining outcomes of cirrhotic patients with acute decompensation (AD) is unknown. We aimed to investigate HCMV incidence and potential correlation with hepatic outcomes in AD patients.
Methods
Two prospective multicentre cohorts with AD patients were investigated. Patients in cohort 1 were recruited from 4 centres, while patients in cohort 2 were randomly selected from a second multicentre cohort. HCMV reactivation was established with quantitative real-time polymerase chain reaction assay in seropositive patients.
Results
HCMV reactivation was found in 35 patients from cohort 1 (n=722) and 14 from cohort 2 (n=291), with an incidence of 4.8% in both cohorts. Bacterial infection and liver failure were independently correlated with HCMV reactivation. HCMV reactivation was an independent predictor of 90-day mortality. Among bacterial infection populations in these two cohorts, patients with HCMV reactivation had worse prognosis compared to those without. Incidence of acute-on-chronic liver failure (ACLF) was higher in patients with HCMV reactivation compared to those without and was also independently correlated with development of ACLF. In a total of 49 HCMV reactivation cases, 8 patients were treated with ganciclovir, in whom a significantly lower 90-day mortality compared with those not treated was observed. All 3 patients who underwent liver transplantation with reactivation of HCMV died.
Conclusions
In AD patients, HCMV reactivation was common, especially in those with bacterial infection or liver failure, and they were more prone to having ACLF and 90‑day mortality. The data propose the need for active surveillance for HCMV infection in AD patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Human cytomegalovirus reactivation in decompensated cirrhosis: marker of immunosuppression or contributor to severity?: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
    Zhujun Cao, Richard Moreau
    Clinical and Molecular Hepatology.2026; 32(2): 953.     CrossRef
  • Correspondence to editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
    Changze Hong, Jinjun Chen
    Clinical and Molecular Hepatology.2026; 32(2): e227.     CrossRef
  • Call for preemptive treatment of cytomegalovirus in patients with cirrhosis and acute decompensation: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
    Norihiro Imai
    Clinical and Molecular Hepatology.2026; 32(2): 949.     CrossRef
  • 4,648 View
  • 145 Download
  • 3 Web of Science
  • Crossref

Review

Liver fibrosis, cirrhosis, and portal hypertension

With the enactment of the ‘Act on Decisions on Life-Sustaining Treatment for Patients in Hospice and Palliative Care or at the End of Life’ (Act No. 14013) in Korea, there is growing concern about the practicality of this law. In this review, we discuss definitions, ethics, and practical issues related to this law.

Citations

Citations to this article as recorded by  Crossref logo
  • Assisted Suicide for Irreversible Patients on Life Support? The Intricate Italian Journey Towards Conforming with the Legislation of Spain, Austria, and Portugal
    Gianluca Montanari Vergallo, Susanna Marinelli, Nicola Di Fazio, Simona Zaami, Paola Frati
    Healthcare.2025; 13(8): 885.     CrossRef
  • Physicians’ experiences and perceptions about withholding and withdrawal life-sustaining treatment in Chiang Mai University Hospital: a cross-sectional study
    Nattanit Ketchaikosol, Kanokporn Pinyopornpanish, Chaisiri Angkurawaranon, Nisachol Dejkriengkraikul, Lalita Chutarattanakul
    BMC Palliative Care.2024;[Epub]     CrossRef
  • Evaluating the Benefits of Transition to Home Palliative Care: Pharmacological Prescriptions, Social, and Psychological Support Post-Referral
    Hugo Ribeiro, João Rocha-Neves, Marília Dourado, José Paulo Andrade
    Journal of Primary Care & Community Health.2024;[Epub]     CrossRef
  • Patient and hospital characteristics associated with do-not-resuscitate/do-not-intubate orders: a cross-sectional study based on the Taiwan stroke registry
    Hsu-Ling Yeh, Fang-I Hsieh, Li-Ming Lien, Wen-Hua Kuo, Jiann-Shing Jeng, Yu Sun, Cheng-Yu Wei, Po-Yen Yeh, Hei-Tung Yip, Cheng-Li Lin, Nicole Huang, Kai-Cheng Hsu
    BMC Palliative Care.2023;[Epub]     CrossRef
  • Diagnostic Value of Non-invasive Scoring Systems in the Prediction of Esophageal Varices in Patients with Liver Cirrhosis—Single Center Experience
    Tijana Glisic, Milica Stojkovic Lalosevic, Tamara Milovanovic, Ivan Rankovic, Marija Stojanovic, Aleksandar Toplicanin, Marko Aleksic, Vladimir Milivojevic, Jelena Martinov Nestorov, Iva Lolic, Dusan D. Popovic
    Medicina.2022; 58(2): 158.     CrossRef
  • Current Medical Treatment for Alcohol-Associated Liver Disease
    Gustavo Ayares, Francisco Idalsoaga, Luis A. Díaz, Jorge Arnold, Juan P. Arab
    Journal of Clinical and Experimental Hepatology.2022; 12(5): 1333.     CrossRef
  • How Do We Start Palliative Care for Patients With End-Stage Liver Disease?
    Sookyung Kim, Kyunghwa Lee, Changhwan Kim, Jahyun Choi, Sanghee Kim
    Gastroenterology Nursing.2022; 45(2): 101.     CrossRef
  • Hospice Care Preferences and Its Associated Factors among Community-Dwelling Residents in China
    Huijing Lin, Eunjeong Ko, Bei Wu, Ping Ni
    International Journal of Environmental Research and Public Health.2022; 19(15): 9197.     CrossRef
  • Nurses' perspectives on advance directives before the establishment of the new well-dying law in Korea: A mixed methods study
    Youn-Jung Son, JiYeon Choi, Jung-Won Ahn
    Applied Nursing Research.2020; 51: 151187.     CrossRef
  • Remaining challenges for the noninvasive diagnosis of esophageal varices in liver cirrhosis
    Tetsuo Takehara, Ryotaro Sakamori
    Esophagus.2020; 17(1): 19.     CrossRef
  • Life-Sustaining Treatment in End-Stage Liver Disease Patients: Patients’ Decisions and Results
    Hyun Jung Jung, Jeong Yun Park
    The Korean Journal of Hospice and Palliative Care.2020; 23(2): 85.     CrossRef
  • Advance care planning in Asian culture
    Shao-Yi Cheng, Cheng-Pei Lin, Helen Yue-lai Chan, Diah Martina, Masanori Mori, Sun-Hyun Kim, Raymond Ng
    Japanese Journal of Clinical Oncology.2020; 50(9): 976.     CrossRef
  • Palliative care and end-stage liver disease
    Mina O. Rakoski, Michael L. Volk
    Current Opinion in Gastroenterology.2019; 35(3): 155.     CrossRef
  • Advance Directive Preferences Among Terminally Ill Older Patients and Its Facilitators and Barriers in China: A Scoping Review
    Jing Liao, Bei Wu, Ping Ni, Jing Mao
    Journal of the American Medical Directors Association.2019; 20(11): 1356.     CrossRef
  • Early Integration of Advance Care Planning (ACP) into Cirrhosis Care: Why We Need It
    Amanda Brisebois, Puneeta Tandon
    Current Hepatology Reports.2018; 17(1): 70.     CrossRef
  • Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy
    Joohwan Bae, Dong Hyun Sinn, Wonseok Kang, Geum‐Youn Gwak, Moon Seok Choi, Yong‐Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
    Liver International.2018; 38(8): 1442.     CrossRef
  • Hospice and Palliative Care in End Stage Liver Disease
    Moon Young Kim
    The Korean Journal of Hospice and Palliative Care.2017; 20(3): 167.     CrossRef
  • 13,247 View
  • 241 Download
  • 15 Web of Science
  • Crossref
Original Articles

Viral hepatitis

Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure
Jung Min Ha, Won Sohn, Ju Yeon Cho, Jeung Hui Pyo, Kyu Choi, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Chul Koh, Seung Woon Paik, Byung Chul Yoo, Yong-Han Paik
Clin Mol Hepatol 2015;21(3):232-241.
Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.232
Background/Aims

Hepatitis-B-related acute-on-chronic liver failure has a poor prognosis. However, the advent of potent oral antiviral agents means that some patients can now recover with medical treatment. We aimed to identify the prognostic factors for hepatitis-B-related acute-on-chronic liver failure including the initial as well as the dynamically changing clinical parameters during admission.

Methods

Sixty-seven patients were retrospectively enrolled from 2003 to 2012 at Samsung Medical Center. The patients were classified into three categories: Recovery group (n=23), Liver transplantation group (n=28), and Death group (n=16). The Liver transplantation and Death groups were combined into an Unfavorable prognosis group. We analyzed the prognostic factors including the Model for End-Stage Liver Disease (MELD) scores determined at 3-day intervals.

Results

A multivariable analysis showed that the unfavorable prognostic factors were a high initial MELD score (≥28) (odds ratio [OR] =6.64, p=0.015), moderate-to-severe ascites at admission (OR=6.71, P=0.012), and the aggravation of hepatic encephalopathy during hospitalization (≥grade III) (OR=15.41, P=0.013). Compared with the baseline level, significant reductions in the MELD scores were observed on the 7th day after admission in the Recovery group (P=0.016).

Conclusions

Dynamic changes in clinical parameters during admission are useful prognostic factors for hepatitis-B-related acute-on-chronic liver failure.

Citations

Citations to this article as recorded by  Crossref logo
  • Plasma galectin-3 can be considered as a non-invasive marker to predict the prognosis of ACLF patients with new typing
    Li Bai, Wang Lu, Qi Yang, Xiaoxuan Liu, Yu Chen, Zhongping Duan
    Scientific Reports.2025;[Epub]     CrossRef
  • Construction of a novel prognostic scoring model for HBV-ACLF liver failure based on dynamic data
    Qun Cai, Hao Wang, Mingyan Zhu, Yixin Xiao, Tingting Zhuo
    Scientific Reports.2024;[Epub]     CrossRef
  • PLT Counts as a Predictive Marker after Plasma Exchange in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
    Xue Li, Hao Li, Yucui Zhu, Huaqian Xu, Shanhong Tang
    Journal of Clinical Medicine.2023; 12(3): 851.     CrossRef
  • Falla hepática aguda sobre crónica: análisis de una serie de casos y revisión de la literatura
    Jhon Edwar García-Rueda, Ricardo Londoño-García, Tomás Marín-Cuartas, Juan Esteban Hernández-Abaunza, Sebastián Osorio-Rico, Angélica María Bermúdez-Flórez, Juan Carlos Restrepo-Gutiérrez
    Hepatología.2022; : 72.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators
    Zhenjun Yu, Yu Zhang, Yingying Cao, Manman Xu, Shaoli You, Yu Chen, Bing Zhu, Ming Kong, Fangjiao Song, Shaojie Xin, Zhongping Duan, Tao Han
    Scientific Reports.2021;[Epub]     CrossRef
  • Clinical Course and Outcome Patterns of Acute-on-chronic Liver Failure: A Multicenter Retrospective Cohort Study
    Man-Man Xu, Ming Kong, Peng-Fei Yu, Ying-Ying Cao, Fang Liu, Bing Zhu, Yi-Zhi Zhang, Wang Lu, Huai-Bin Zou, Bin-Wei Duan, Shao-Li You, Shao-Jie Xin, Tao Han, Zhong-Ping Duan, Yu Chen
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2019; 25(2): 93.     CrossRef
  • A Dynamic Model for Predicting Outcome in Patients with HBV Related Acute-On-Chronic Liver Failure
    Wei Lin, Jing Zhang, Xiaohui Liu, Hongqun Liu, Jinqiu He, Ming Li, Shuqin Zhang, Hong Chen, Changqing Zhang, Wenfang Wu, Chenggang Jin, Samuel S. Lee, Zhongping Duan, Yuexin Zhang
    Annals of Hepatology.2018; 17(3): 392.     CrossRef
  • 12,198 View
  • 96 Download
  • 9 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites
Jun Jae Kim, Jeong Han Kim, Ja Kyung Koo, Yun Jung Choi, Soon Young Ko, Won Hyeok Choe, So Young Kwon
Clin Mol Hepatol 2014;20(1):47-55.
Published online March 26, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.1.47
Background/Aims

The modification of the Model for End-Stage Liver Disease (MELD) scoring system (Refit MELD) and the modification of MELD-Na (Refit MELDNa), which optimized the MELD coefficients, were published in 2011. We aimed to validate the superiority of the Refit MELDNa over the Refit MELD for the prediction of 3-month mortality in Korean patients with cirrhosis and ascites.

Methods

We reviewed the medical records of patients admitted with hepatic cirrhosis and ascites to the Konkuk University Hospital between January 2006 and December 2011. The Refit MELD and Refit MELDNa were compared using the predictive value of the 3-month mortality, as assessed by the Child-Pugh score.

Results

In total, 530 patients were enrolled, 87 of whom died within 3 months. Alcohol was the most common etiology of their cirrhosis (n=271, 51.1%), and the most common cause of death was variceal bleeding (n=20, 23%). The areas under the receiver operating curve (AUROCs) for the Child-Pugh, Refit MELD, and Refit MELDNa scores were 0.754, 0.791, and 0.764 respectively; the corresponding values when the analysis was performed only in patients with persistent ascites (n=115) were 0.725, 0.804, and 0.796, respectively. The significant difference found among the Child-Pugh, Refit MELD, and Refit MELDNa scores was between the Child-Pugh score and Refit MELD in patients with persistent ascites (P=0.039).

Conclusions

Refit MELD and Refit MELDNa exhibited good predictability for 3-month mortality in patients with cirrhosis and ascites. However, Refit MELDNa was not found to be a better predictor than Refit MELD, despite the known relationship between hyponatremia and mortality in cirrhotic patients with ascites.

Citations

Citations to this article as recorded by  Crossref logo
  • Multimodal ultrasound: a non-invasive method for identifying dedifferentiation of papillary thyroid carcinoma during active surveillance
    Qian-Yi Dou, Huan-Ling Guo, Wan-Bing Qiu, Ming Xu, Shu-Ling Chen, Xiao-Er Zhang, Xiao-Yan Xie, Jin-Yu Liang
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • The diagnostic accuracy of ascitic calprotectin for the early diagnosis of spontaneous bacterial peritonitis: systematic review and meta-analysis
    Alexandros Hadjivasilis, Alexander Tzanis, Kalliopi J. Ioakim, Ioanna Poupoutsi, Aris P. Agouridis, Panayiotis Kouis
    European Journal of Gastroenterology & Hepatology.2021; 33(3): 312.     CrossRef
  • Influence of preoperative sodium concentration on outcome of patients with hepatitis B virus cirrhosis after liver transplantation
    Peijie Wang, Gang Huang, Ngalei Tam, Chenglin Wu, Shunjun Fu, Bridget P. Hughes, Linwei Wu, Xiaoshun He
    European Journal of Gastroenterology & Hepatology.2016; 28(10): 1210.     CrossRef
  • 9,784 View
  • 51 Download
  • 6 Web of Science
  • Crossref
Comparison of the Model for End-stage Liver Disease and hepatic venous pressure gradient for predicting survival in patients with decompensated Liver cirrhosis
Sung Hoa Lee, M.D., Seung Ha Park, M.D., Go Woon Kim, M.D., Woo Jin Lee, M.D., Won Ki Hong, M.D., Myeong Shin Ryu, M.D., Kyu Tae Park, M.D., Min Young Lee, M.D., Chan Woo Lee, M.D., Jin Ho Kim, M.D., Yong Mook Kim, M.D., Sung Jung Kim, M.D., Gwang Ho Baik, M.D., Jin Bong Kim, M.D., Dong Joon Kim, M.D.
Korean J Hepatol 2009;15(3):350-356.
Published online September 30, 2009
DOI: https://doi.org/10.3350/kjhep.2009.15.3.350
Backgrounds/Aims
This study compared the prognostic values of the Model for End-stage Liver Disease (MELD) and the hepatic venous pressure gradient (HVPG) in the prediction of death within 3 and 12 months in patients with decompensated liver cirrhosis. Methods: We used data from 136 consecutive patients with decompensated cirrhosis who underwent HVPG between January 2006 and June 2008. Cox regression analysis was used to investigate the independent relationships with death of MELD and HVPG. The prognostic accuracies of MELD and HVPG were analyzed by calculating the area under the receiver operating characteristic curve (AUROC) for the occurrence of death within 3 and 12 months. Results: Both MELD and HVPG were independent predictors of death [hazard ratio (HR)=1.11 and 1.12, respectively; 95% confidence interval (CI)=1.04~1.20 and 1.08-1.16]. Analysis of the AUROC demonstrated that the prognostic power did not differ between MELD and HVPG for predicting the 3-month survival (HR=0.76 and 0.68, respectively; 95% CI=0.62~0.89 and 0.52~0.84; P=0.22) or the 12-month survival (HR=0.72 and 0.73, 95% CI=0.61~0.83 and CI=0.61~0.84). Conclusions: Both MELD and HVPG are independent prognostic factors of death within 3 and 12 months in patients with decompensated liver cirrhosis, and their accuracies are similar. However, HVPG has a limited role in the prediction of death in decompensated cirrhosis due to its invasiveness and limited use. (Korean J Hepatol 2009;15:350-356)

Citations

Citations to this article as recorded by  Crossref logo
  • Hepatic Venous Pressure Gradient Predicts Long-Term Mortality in Patients with Decompensated Cirrhosis
    Tae Yeob Kim, Jae Gon Lee, Joo Hyun Sohn, Ji Yeoun Kim, Sun Min Kim, Jinoo Kim, Woo Kyoung Jeong
    Yonsei Medical Journal.2016; 57(1): 138.     CrossRef
  • Evaluation of portal hypertension by real‐time shear wave elastography in cirrhotic patients
    Tae Yeob Kim, Woo Kyoung Jeong, Joo Hyun Sohn, Jinoo Kim, Min Yeong Kim, Yongsoo Kim
    Liver International.2015; 35(11): 2416.     CrossRef
  • Relationship between the hepatic venous pressure gradient and first variceal hemorrhage in patients with cirrhosis: a multicenter retrospective study in Korea
    Jin Nyoung Kim, Kyoung Min Sohn, Moon Young Kim, Ki Tae Suk, Soung Won Jeong, Ho Eun Jung, Sae Hwan Lee, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Soon Koo Baik, Hong Soo Kim, Dong Joon Kim, Boo Sung Kim
    Clinical and Molecular Hepatology.2012; 18(4): 391.     CrossRef
  • 6,677 View
  • 30 Download
  • Crossref